FDA GLP-1 Alerts & Regulatory Actions
Warning letters, recalls, shortage updates, and regulatory changes affecting GLP-1 medications and compounding pharmacies. Sourced from public FDA records.
Latest FDA alerts
FDA Issues Warning Letters to 7 Companies Marketing Unapproved GLP-1 Products
The FDA sent warning letters to seven companies for selling products marketed as GLP-1 receptor agonists that were not approved, cleared, or authorized by the FDA.
FDA Announces Intent to Restrict Ingredients in Mass-Marketed Compounded GLP-1 Drugs
The FDA announced plans to limit certain ingredients used in compounded GLP-1 medications that are marketed on a large scale, signaling tighter regulation of the compounding industry.
FDA Issues 30 Warning Letters to GLP-1 Telehealth Companies for Misleading Marketing
The FDA sent warning letters to 30 telehealth companies for making false or misleading marketing claims about compounded GLP-1 medications, including claims of equivalence to FDA-approved products.
FDA Officially Resolves Semaglutide Injection Shortage
The FDA announced that the semaglutide injection shortage has been officially resolved, which changes the legal basis for some compounding of semaglutide products.
FDA Updates Safety Communication on Compounded GLP-1 Drugs for Weight Loss
The FDA updated its safety communication highlighting concerns about unapproved compounded GLP-1 drugs used for weight loss, citing over 1,100 adverse event reports.
About this data: All alerts are sourced from public FDA records. This page is for informational purposes only and does not constitute medical or legal advice. Always verify with official FDA sources.
GLP-1 Safety Alerts
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.